Bryan Downie

1.2k total citations
26 papers, 537 citations indexed

About

Bryan Downie is a scholar working on Genetics, Rheumatology and Molecular Biology. According to data from OpenAlex, Bryan Downie has authored 26 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Rheumatology and 6 papers in Molecular Biology. Recurrent topics in Bryan Downie's work include Chronic Lymphocytic Leukemia Research (12 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Bryan Downie is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Bryan Downie collaborates with scholars based in United States, Germany and United Kingdom. Bryan Downie's co-authors include Luis A. Pardo, Walter Stühmer, Claudia Weber, Fernanda Mello de Queiroz, Matthias Platzer, Philipp Koch, Marco Gymnopoulos, Constanza Contreras‐Jurado, Araceli Sánchez and Afsaneh Mozaffarian and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Bryan Downie

24 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan Downie United States	9	336	93	67	63	57	26	537
Marcel Vergés Spain	16	663 2.0×	135 1.5×	61 0.9×	13 0.2×	104 1.8×	27	1.0k
Aleksandr V. Makeyev United States	13	623 1.9×	87 0.9×	29 0.4×	13 0.2×	30 0.5×	17	853
W. J. Craigen United States	15	635 1.9×	28 0.3×	35 0.5×	33 0.5×	40 0.7×	17	782
Mauro Cerretani Italy	11	262 0.8×	17 0.2×	157 2.3×	39 0.6×	18 0.3×	15	537
Diana L. Walker United States	10	397 1.2×	30 0.3×	183 2.7×	18 0.3×	56 1.0×	13	679
U Utans United States	9	372 1.1×	65 0.7×	46 0.7×	24 0.4×	39 0.7×	11	742
Yutaka Furutani Japan	14	258 0.8×	24 0.3×	51 0.8×	7 0.1×	77 1.4×	35	602
Masumi Endoh Japan	13	202 0.6×	28 0.3×	64 1.0×	71 1.1×	35 0.6×	26	633
Anke H.M. van Vugt Netherlands	14	435 1.3×	16 0.2×	43 0.6×	60 1.0×	42 0.7×	18	674
Marianna Di Scala Spain	13	215 0.6×	13 0.1×	126 1.9×	15 0.2×	28 0.5×	18	476

Countries citing papers authored by Bryan Downie

Since Specialization

Citations

This map shows the geographic impact of Bryan Downie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Downie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Downie more than expected).

Fields of papers citing papers by Bryan Downie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Downie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Downie. The network helps show where Bryan Downie may publish in the future.

Co-authorship network of co-authors of Bryan Downie

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Downie. A scholar is included among the top collaborators of Bryan Downie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Downie. Bryan Downie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allweiss, Lena, Vithika Suri, Jeffrey J. Wallin, et al.. (2024). Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. Journal of Hepatology. 80(6). 882–891. 18 indexed citations

Taylor, Peter C., et al.. (2024). Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis. Rheumatology and Therapy. 11(5). 1383–1392.

Pan, David Z., Cameron M. Soulette, Abhishek Aggarwal, et al.. (2024). Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B. Gut. 74(4). 628–638. 4 indexed citations

Funderburg, Nicholas, Calvin Cohen, Jean C. Lee, et al.. (2024). Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens. Frontiers in Immunology. 15. 1488799–1488799. 2 indexed citations

Curtis, Jeffrey R., Paul Emery, Bryan Downie, et al.. (2023). Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis. Rheumatology and Therapy. 11(1). 177–189. 3 indexed citations

Tanaka, Yoshiya, Peter C. Taylor, Emon Elboudwarej, et al.. (2023). Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate. Rheumatology and Therapy. 10(5). 1335–1348. 1 indexed citations

Pan, David Z., Pamela M. Odorizzi, Mazin Abdelghany, et al.. (2023). Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting. SHILAP Revista de lepidopterología. 3(1). 2–2. 4 indexed citations

Price, Elizabeth, Stefano Bombardieri, Alan Kivitz, et al.. (2022). Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Lara D. Veeken. 61(12). 4797–4808. 46 indexed citations

Rahman, Md. Taibur, Bryan Downie, Gabriela Salinas, et al.. (2021). The Redox Homeostasis of Skeletal Muscle Cells Regulates Stage Differentiation of Toxoplasma gondii. Frontiers in Cellular and Infection Microbiology. 11. 798549–798549. 6 indexed citations

10.

Werth, Victoria P., Roy Fleischmann, Zahi Touma, et al.. (2021). Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Lara D. Veeken. 61(6). 2413–2423. 43 indexed citations

11.

Taylor, Peter C., et al.. (2020). THU0216 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN METHOTREXATE NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (FINCH3). Annals of the Rheumatic Diseases. 79. 333–334. 1 indexed citations

12.

Clarke, Astrid, et al.. (2020). P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis. Journal of Crohn s and Colitis. 14(Supplement_1). S409–S409.

13.

Taylor, Peter C., Bryan Downie, Emon Elboudwarej, et al.. (2020). THU0215 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1). Annals of the Rheumatic Diseases. 79. 333–333. 1 indexed citations

14.

Podlaha, Ondřej, George Y. Wu, Bryan Downie, et al.. (2019). Genomic modeling of hepatitis B virus integration frequency in the human genome. PLoS ONE. 14(7). e0220376–e0220376. 36 indexed citations

15.

Taylor, Peter C., et al.. (2019). THU0194 SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB MODULATES THE DISEASE-ASSOCIATED WHOLE BLOOD TRANSCRIPTIONAL PROFILE OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 78. 374–375. 1 indexed citations

16.

Downie, Bryan, et al.. (2017). Histone deacetylase inhibitor MS-275 augments expression of a subset of IFN-γ-regulated genes in Toxoplasma gondii-infected macrophages but does not improve parasite control. Experimental Parasitology. 180. 45–54. 5 indexed citations

17.

Pardo, Luis A., David Gómez‐Varela, Kamonchanok Sansuk, et al.. (2012). Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy. Current Medicinal Chemistry. 19(5). 675–682. 28 indexed citations

18.

Downie, Bryan, Araceli Sánchez, Constanza Contreras‐Jurado, et al.. (2008). Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors. Journal of Biological Chemistry. 283(52). 36234–36240. 138 indexed citations

19.

Weber, Claudia, et al.. (2006). Silencing the Activity and Proliferative Properties of the Human EagI Potassium Channel by RNA Interference. Journal of Biological Chemistry. 281(19). 13030–13037. 105 indexed citations

20.

Weber, Claudia, et al.. (2006). Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNA interference. VOLUME 281 (2006) PAGES 13030-13037. Journal of Biological Chemistry. 281(25). 17540–17540. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact